[go: up one dir, main page]

PE20240881A1 - Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t - Google Patents

Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t

Info

Publication number
PE20240881A1
PE20240881A1 PE2024000331A PE2024000331A PE20240881A1 PE 20240881 A1 PE20240881 A1 PE 20240881A1 PE 2024000331 A PE2024000331 A PE 2024000331A PE 2024000331 A PE2024000331 A PE 2024000331A PE 20240881 A1 PE20240881 A1 PE 20240881A1
Authority
PE
Peru
Prior art keywords
preparation
treatment
drugs
ezh2 inhibitor
lymphocyte lymphoma
Prior art date
Application number
PE2024000331A
Other languages
English (en)
Inventor
Xiaojing Zhang
Weiwei Wang
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of PE20240881A1 publication Critical patent/PE20240881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de un inhibidor de EZH2 en la preparacion de un farmaco para el tratamiento de linfoma de linfocitos T. Especificamente, la presente invencion se refiere al uso de un compuesto segun se representa en la formula (I) o una sal farmaceuticamente aceptable del mismo en la preparacion de un farmaco para el tratamiento de linfoma de linfocitos T. Ademas, menciona la dosis administrada del compuesto de la formula (I) o la sal farmaceuticamente aceptable.
PE2024000331A 2021-08-30 2022-08-30 Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t PE20240881A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111001663 2021-08-30
PCT/CN2022/115763 WO2023030299A1 (zh) 2021-08-30 2022-08-30 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途

Publications (1)

Publication Number Publication Date
PE20240881A1 true PE20240881A1 (es) 2024-04-24

Family

ID=85411942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000331A PE20240881A1 (es) 2021-08-30 2022-08-30 Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t

Country Status (16)

Country Link
US (1) US20240325371A1 (es)
EP (1) EP4393490A4 (es)
JP (1) JP2024530310A (es)
KR (1) KR20240056564A (es)
CN (1) CN117956995A (es)
AU (1) AU2022340500A1 (es)
CA (1) CA3230149A1 (es)
CL (1) CL2024000593A1 (es)
CO (1) CO2024003923A2 (es)
CR (1) CR20240147A (es)
IL (1) IL311097A (es)
MA (1) MA65131B1 (es)
MX (1) MX2024002538A (es)
PE (1) PE20240881A1 (es)
TW (1) TW202327597A (es)
WO (1) WO2023030299A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9006242B2 (en) * 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
EP3378859B1 (en) * 2015-11-19 2019-10-30 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
CN108314677B (zh) * 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
TWI772424B (zh) * 2017-05-18 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
US12473298B2 (en) * 2019-03-25 2025-11-18 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Amide compounds, preparation method therefor, and use thereof in the medical field
TW202108578A (zh) * 2019-05-10 2021-03-01 大陸商江蘇恒瑞醫藥股份有限公司 6-取代氨基苯并呋喃化合物的製備方法
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途

Also Published As

Publication number Publication date
KR20240056564A (ko) 2024-04-30
MX2024002538A (es) 2024-03-19
EP4393490A4 (en) 2025-08-27
CO2024003923A2 (es) 2024-06-27
JP2024530310A (ja) 2024-08-16
MA65131B1 (fr) 2025-05-30
US20240325371A1 (en) 2024-10-03
CA3230149A1 (en) 2023-03-09
CL2024000593A1 (es) 2024-07-05
CN117956995A (zh) 2024-04-30
TW202327597A (zh) 2023-07-16
WO2023030299A1 (zh) 2023-03-09
IL311097A (en) 2024-04-01
EP4393490A1 (en) 2024-07-03
AU2022340500A1 (en) 2024-04-11
CR20240147A (es) 2024-09-20
MA65131A1 (fr) 2024-11-29

Similar Documents

Publication Publication Date Title
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
UY39529A (es) Nuevos agentes antivirales derivados de espiropirrolidina
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
RU2013121788A (ru) Ингибиторы репликации вич
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CL2024003460A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2023011920A (es) Compuestos de 1,3,4-oxadiazol tiocarbonilo como inhibidores de histona deacetilasa 6, y composicion farmaceutica que los comprende.
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
MX2025010357A (es) Degradador de irak4, y uso del mismo
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.